Physician profile
Grace Pearce
NPI 1508542077
$1,283.66
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,283.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $274.21 | 2024 | |
| Janssen Pharmaceuticals, INC | $218.06 | 2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.34 | 2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $156.44 | 2024 | Hetlioz, Fanapt |
| Alkermes, INC. | $70.27 | 2024 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $67.02 | 2024 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $65.35 | 2024 | Rexulti |
| Novo Nordisk INC | $56.78 | 2024 | Wegovy |
| Axsome Therapeutics, INC. | $41.68 | 2024 | Auvelity |
| Almatica Pharma LLC | $34.48 | 2024 | Loreev Xr |
| Neos Therapeutics, LP | $28.68 | 2024 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $28.49 | 2024 | Trintellix |
| Neurocrine Biosciences, INC. | $24.17 | 2024 | Ingrezza |
| Braeburn INC. | $20.72 | 2024 | Brixadi |
| Bausch Health US, LLC | $19.78 | 2024 | Aplenzin |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $15.19 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Pearce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.